Industry News

EnteroMedics Inc., the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced the publication of 24 month results from the Company's ReCharge Clinical Study. The article, titled "Two-Year Outcomes of Vagal Nerve Blocking for the Treatment of Obesity in the ReCharge Trial," was published in Obesity Surgery, and is available online here."/>
EnteroMedics Announces Publication of 24 Month ReCharge Clinical Study Data in Obesity Surgery
Mirna Therapeutics, Inc., a clinical stage biopharmaceutical company developing a pipeline of microRNA-based oncology therapeutics, today reported financial results for the second quarter of 2016 and provided an update on recent developments. MRX34 CLINICAL PROGRAM AND SECOND QUARTER UPDATE. Presented clinical data of MRX34 at ASCO 2016. In an oral presentation, investigators reported on the final dose-escalation results from the first-in-human Phase 1..."/>
Mirna Therapeutics Reports Second Quarter 2016 Financial Results and Program Updates
Arch Therapeutics, Inc., developer of devices for use in controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, successfully met the objectives of its recently completed single-center, randomized, single-blind prospective clinical study of the AC5 Topical Hemostatic Device in skin lesion patients with bleeding wounds. This was the first study assessing the safety and performance of AC5 in humans."/>
Arch Therapeutics Reports AC5 Topical Hemostatic Device Meets Primary and Secondary Endpoints in First Clinical Study
MEDNAX, Inc., today announced the acquisition of Maternal Fetal Medicine of Southwest Florida, P.A. a private physician group practice based in Fort Myers, Fla. Maternal Fetal Medicine of Southwest Florida was established in 2000 and currently has four physicians, 11 sonographers and 26 other clinical and administrative staff who provide a full spectrum of perinatology and sonographic services including comprehensive high-risk maternal-fetal..."/>
MEDNAX Announces Acquisition of Maternal-Fetal Medicine Practice in Florida
Teleflex Launches Ambitious Efforts to Accelerate Growing Acceptance Worldwide of Percutaneous Laparoscopy Now Performed in 14 Countries. WAYNE, Pa.---- Teleflex Incorporated, a leading global provider of medical technologies for critical care and surgery, has announced today that it has officially launched its second-generation..."/>
Teleflex Launches New Second-Generation 2.9 mm Percuvance® System – A Breakthrough Advance that Makes Percutaneous Approach to Laparoscopic Procedures Even Less Invasive
ChromaDex Corp., an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions to dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that the U.S. Food and Drug Administration has issued a generally recognized as safe No Objection Letter, in response to the NIAGEN ® nicotinamide riboside chloride GRAS filing, Notice No."/>
U.S. FDA issues GRAS No Objection Letter for NIAGEN®
Arrowhead Pharmaceuticals reported on Friday the completion of USD45m in private offering with a select group of investors, including Orbimed, RA Capital Management, Perceptive Advisors, RTW Investments and certain other institutional investors. In the private offering, about 7.63 m shares of common stock were issued at a price of USD5.90 per share. Cantor Fitzgerald& Co acted as sole placement agent for the private offering."/>
Arrowhead Pharmaceuticals raises USD45m from private offering of common stock
Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, today announced that it will release its unaudited financial results for the second quarter, ended June 30, 2016, before the market opens on Tuesday, August 23, 2016. The Company will host a conference call the same day, Tuesday, August 23, 2016, at 8:00 a.m. EDT to review the Company's financial results and provide an update on recent corporate developments."/>
Sinovac to Host Conference Call to Report Second Quarter and 2016 Unaudited Financial Results
Exact Sciences Corp. announced that the Centers for Medicare and Medicaid Services issued an updated Evidence of Coverage notice for Medicare Advantage plans that affirms such plans must include coverage of Cologuard every three years without patient coinsurance, copayments or deductibles. "The CMS update assures patients and physicians that Cologuard is covered by Medicare Advantage plans without any out-of-pocket costs," said..."/>
CMS Affirms Cologuard® Covered Every Three Years for Medicare Advantage Beneficiaries without Cost Sharing
Cynapsus Therapeutics Inc., a specialty central nervous system pharmaceutical company developing and preparing to commercialize a fast-acting, easy-to-use, sublingual thin film for the on-demand management of debilitating OFF episodes associated with Parkinson’ s disease, announced today that its Data Safety and Monitoring Board has completed a review of the safety data from the Company’ s Phase 3 program including both the CTH-300 and CTH-301..."/>
Cynapsus Announces Positive Opinion from Data and Safety Monitoring Board on Phase 3 Parkinson’s Disease Clinical Study Allowing for At-Home Titration
Cynapsus Therapeutics Inc., a specialty central nervous system pharmaceutical company developing and preparing to commercialize a fast-acting, easy-to-use, sublingual thin film for the on-demand management of debilitating OFF episodes associated with Parkinson's disease, announced today that its Data Safety and Monitoring Board has completed a review of the safety data from the Company's Phase 3 program including both the CTH-300 and CTH-301..."/>
Cynapsus Announces Positive Opinion from Data and Safety Monitoring Board on Phase 3 Parkinson's Disease Clinical Study Allowing for At-Home Titration
Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company focused on the global immunology market, today announced positive top-line results..."/>
Aurinia Pharmaceuticals Announces Voclosporin Meets Primary Endpoint in Phase IIB AURA-LV Study in Lupus Nephritis
Ekso Bionics Holdings revealed on Friday the completion of its public offering of 3,750,000 shares of its common stock. All of the shares in the public offering has been issued by the company at a price of USD4.00 per share for expected net proceeds of about USD13.7m, after deducting underwriting discounts and offering expenses. The company has provided the underwriters with a 30- day option to purchase an additional 562,500 shares at the public..."/>
Ekso Bionics Holdings concludes public offering of common stock at USD4.00 per share
Supernus Pharmaceuticals announced on Friday the departure M. James Barrett, PhD from its board of directors with effect from 10 August 2016.. Currently, Dr Barrett is the partner emeritus at New Enterprise Associates, a venture capital firm. Dr Barret has served as the chairman of the board of directors at the company since 2005 when NEA was its lead investor."/>
Supernus reports change in board members
Arrowhead Pharmaceuticals Inc. has closed a previously announced private offering with a select group of investors including Orbimed, RA Capital Management, Perceptive Advisors, RTW Investments and certain other institutional investors, the company said. Gross proceeds were USD45 million. Approximately 7.63 million shares of common stock were issued at a price of USD5.90 per share."/>
Arrowhead Pharmaceuticals closes USD45m private offering
Mazor Robotics Ltd., a pioneer and a leader in the field of surgical guidance systems, today announced the completion of the second tranche of the equity investment by Medtronic pursuant to a previously executed agreement between the parties. The Company issued new securities representing 3.40% percent of Mazor's issued and outstanding share capital, on a fully diluted basis, at a price per ADS $21.84, which is equal to the volume weighted average price of the..."/>
Medtronic Completes $20 Million Second Tranche Investment in Mazor Robotics
Piramal Enterprises Ltd is set to make its second investment in the renewable energy sector this year with an investment of Rs.800 crore in solar power producer ACME Solar, reported Mint."/>
Deals Buzz: Hindalco's Novelis unit to raise up to $1.1 billion [Mint, New Delhi]
Sun Pharmaceutical Industries Ltd. Earlier last week, its US unit Taro Pharmaceutical Industries Ltd reported lower-than expected sales, declining sequentially by 11.6% to $234 million. Competition and its effect on drug prices are affecting sales growth. Sun Pharma's own sales growth in the US market rose 19% sequentially to $375 million."/>
Sun Pharma: hopes pinned on FDA clearance for Halol plant [Mint, New Delhi]
Piramal Enterprises Ltd is set to make its second investment in the renewable energy sector this year with an investment of Rs.800 crore in solar power producer ACME Solar, according to two people aware of the development. The investment in Delhi-based ACME is being done by Piramal Enterprises' Structured Investment Group, which provides structured mezzanine funding to companies in various sectors, especially in infrastructure."/>
Piramal in talks to invest Rs800 crore in ACME Solar [Mint, New Delhi]
M and A Navigator: Deal pipeline –15 August
Flamel Technologies SA has received shareholder approval to reincorporate its country of domicile to Ireland from France via a cross-border merger, the company said. Shareholders voted in favour of the reincorporation by proxy at the company's extraordinary general meeting, held in Lyon, France on 10 August, 2016.. Under the terms of the company's reincorporation, Flamel will merge with and into its wholly owned..."/>
Shareholders of French Drugmaker Flamel Approve Cross-Border Merger
Mednax, Inc. has acquired Fort Myers, Florida-based private physician group Maternal Fetal Medicine of Southwest Florida, PA, the company said. This was a cash transaction, and it is expected to be immediately accretive to earnings. No additional terms of the transaction were disclosed."/>
Mednax Acquires Maternal-Fetal Medicine Practice in Florida

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Consumer Discretionary630 Articles
Information Technology609 Articles
Financials502 Articles
Health Care362 Articles
Industrials345 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.